|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
86,097,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Annexon is a clinical-stage biopharmaceutical company developing a class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Co. is developing a pipeline of product candidates designed to block the activity of C1q and the entire classical complement pathway for a range of complement-mediated diseases. Co.'s pipeline includes three clinical-stage assets across three therapeutic franchises: autoimmune, neurodegenration and ophtamology. Co. its developing its primary candidate, ANX005.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
3,200 |
353,200 |
653,200 |
5,754,246 |
| Total Buy Value |
$19,411 |
$1,027,411 |
$1,667,131 |
$29,090,439 |
| Total People Bought |
1 |
2 |
3 |
3 |
| Total Buy Transactions |
1 |
2 |
3 |
5 |
| Total Shares Sold |
17,898 |
59,898 |
62,990 |
73,114 |
| Total Sell Value |
$98,919 |
$288,851 |
$300,713 |
$361,680 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
7 |
9 |
12 |
17 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bcip Life Sciences Associates, Lp |
10% Owner |
– – • |
2023-05-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,401,926 |
|
- |
|
| Bcip Life Sciences Associates, Lp |
10% Owner |
– – • |
2023-05-25 |
4 |
B |
$2.13 |
$639,720 |
I/I |
300,000 |
5,701,926 |
1.5 |
- |
|
| Yednock Ted |
EVP & Chief Innovation Officer |
• – – |
2023-03-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
21,000 |
|
- |
|
| Yednock Ted |
EVP & Chief Innovation Officer |
• – – |
2023-03-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
38,942 |
|
- |
|
| Lew Jennifer |
EVP & Chief Financial Officer |
• – – |
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,975 |
48,517 |
|
- |
|
| Overdorf Michael |
EVP & Chief Business Officer |
• – – |
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,975 |
46,780 |
|
- |
|
| Love Douglas |
President & CEO |
• • – |
2023-02-15 |
4 |
S |
$5.87 |
$38,564 |
D/D |
(6,571) |
197,646 |
|
- |
|
| Lew Jennifer |
EVP & Chief Financial Officer |
• – – |
2023-02-14 |
4 |
S |
$6.30 |
$1,046 |
D/D |
(166) |
29,542 |
|
- |
|
| Overdorf Michael |
EVP & Chief Business Officer |
• – – |
2023-02-14 |
4 |
S |
$6.30 |
$907 |
D/D |
(144) |
27,805 |
|
- |
|
| Lew Jennifer |
EVP & Chief Financial Officer |
• – – |
2023-02-13 |
4 |
S |
$6.31 |
$10,989 |
D/D |
(1,742) |
29,708 |
|
- |
|
| Overdorf Michael |
EVP & Chief Business Officer |
• – – |
2023-02-13 |
4 |
S |
$6.30 |
$9,461 |
D/D |
(1,501) |
27,949 |
|
- |
|
| Satter Muneer A |
Director |
– • • |
2023-02-10 |
4 |
B |
$6.80 |
$17,999,994 |
I/I |
2,647,058 |
7,056,024 |
2.25 |
- |
|
| Artis Dean Richard |
EVP & Chief Scientific Officer |
• – – |
2023-01-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,329 |
|
- |
|
| Overdorf Michael |
EVP & Chief Business Officer |
• – – |
2022-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,375 |
21,875 |
|
- |
|
| Lew Jennifer |
EVP & Chief Financial Officer |
• – – |
2022-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
9,375 |
23,875 |
|
- |
|
| Mattheakis Larry |
EVP & Chief Scientific Officer |
• – – |
2022-07-11 |
4 |
A |
$0.00 |
$0 |
D/D |
4,688 |
17,188 |
|
- |
|
| Satter Muneer A |
Director |
– • – |
2022-07-07 |
4 |
B |
$3.84 |
$9,423,314 |
I/I |
2,453,988 |
4,408,966 |
2.1 |
- |
|
| Love Douglas |
President & CEO |
• • – |
2022-04-14 |
4 |
B |
$2.45 |
$146,814 |
D/D |
60,000 |
200,942 |
2.81 |
- |
|
| Mattheakis Larry |
EVP & Chief Scientific Officer |
• – – |
2022-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
12,500 |
|
- |
|
| Overdorf Michael |
EVP & Chief Business Officer |
• – – |
2022-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
12,500 |
|
- |
|
| Keswani Sanjay |
EVP & Chief Medical Officer |
• – – |
2022-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
12,500 |
|
- |
|
| Lew Jennifer |
EVP & Chief Financial Officer |
• – – |
2022-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
14,500 |
|
- |
|
| Love Douglas |
President & CEO |
• • – |
2022-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
140,942 |
|
- |
|
| Love Douglas |
President & CEO |
• • – |
2021-11-11 |
4 |
OE |
$1.41 |
$155,503 |
D/D |
100,942 |
100,942 |
|
- |
|
| Love Douglas |
President & CEO |
• • – |
2021-09-16 |
4 |
AS |
$22.05 |
$165,341 |
D/D |
(7,500) |
0 |
|
- |
|
36 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
